1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Companion Diagnostics: Technologies and Markets

Companion Diagnostics: Technologies and Markets

  • August 2021
  • 254 pages
  • ID: 5285120
  • Format: PDF
  • BCC Research


Table of Contents

Report Scope:
This new report, “Companion Diagnostics: Global Markets,” provides a comprehensive analysis of the CDx market in the global context, including market forecasts and sales through 2026.The report analyzes the market by segmenting it into the various product offerings: consumables (reagents, kits and panels), services and software.

The segmentation also provides analysis by popular technology types such as PCR, next-generation sequencing, in situ hybridization (ISH), immunohistochemistry (IHC) and others.

This study surveys the CDx market by application into different therapeutic areas.The market is also assessed in three major geographic regions: North America, Europe and Asia-Pacific (APAC).

The APAC markets include countries like India, China, Korea, Japan, Taiwan, Australia and New Zealand.

The report features new product developments, clinical trials and patents boosting the growth of this market in the global context.

The new report provides comprehensive profiles of market players in the industry.The industry structure chapter focuses on the changing market trends, market players and their leading products.

This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in this market are evaluated in detail.

The scope of the report excludes the in vitro diagnostic products and their regulatory aspects. Also excluded are the nucleic acid-based tests in general, focusing solely on the companion diagnostics that meet the FDA definition.

Report Includes:
- 53 data tables and 44 additional tables
- An overview of the global market for companion diagnostic (CDx) technologies
- Analyses of the global market trends, with data from 2019-2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation of current market size, market forecast, and technological advancements within the industry and discussion on technical issues related to biomarker stability and storage
- Market share analysis of global CDx market by solution and type of test, technology, application, and geographic region
- Information on biomarkers, their role in precision medicine and discussion on potential use of biomarkers in the development of companion diagnostics (CDx)
- Insights into CDx approvals and FDA guidelines for new drugs and description of predictive genomic biomarkers for immunotherapy including microsatellite instability (MSI) and tumor mutational burden (TMB)
- Coverage of new CDx product developments, clinical trials, patents issued, mergers and acquisitions, partnerships, collaborations and other effective market development strategies
- Comprehensive company profiles of major industry players, including Adaptive Biotechnologies, Exact Sciences Corp., Exosome Diagnostics Inc., Foundation Medicine Inc., Myriad Genetic Laboratories Inc., Roche Molecular Systems Inc., Prometheus Biosciences, Qiagen and Thermo Fisher Scientific Inc.

Pharmacotherapy, as we know it, is undergoing a dramatic transition.The growing knowledge that pharmacotherapy can be highly variable from one patient to another, largely driven by the patient’s genetic and phenotypic heterogeneity, has given rise to the concept of personalized or precision therapy.

Further, advances in the research and development of novel molecular biomarkers that point to single gene variations responsible for disease identification and prognosis have aided in the development of companion diagnostics (CDx) tests. A particular application of CDx is in the treatment decision process—that is, to guide the use of targeted drugs.

The employment of CDx has seen extensive adoption in the field of cancer. The development of targeted therapies that rely on specific genetic biomarkers have given a boost to the use of CDx tests that are being increasingly employed to identify the likely responders and non-responders of those therapies.This is exemplified by the 45 FDA-approved CDx and thousands of other lab-developed tests (LDTs) that are available from small- to medium-sized diagnostic laboratories. In fact, many leading specialized laboratories—namely, LabCorp, Quest Diagnostics, Myriad Genetics, Foundation Medicine, ARUP Laboratories, NeoGenomics and many others—are working towards the development of precision
medicine-directed CDx assays.

Since they benefit patients directly, CDx are proving to be efficient cost-saving tools for drug developers, healthcare systems and payers alike.Several studies and industry expert reviews have highlighted the billions of dollars’ worth of savings that are possible due to the use of CDx in medical systems.

Driven by their potential applications in clinical studies and benefits for patient populations, the CDx are gaining adoption in other disease areas as well, including neurological diseases and cardiovascular diseases, as well as potential decision-making tools for novel therapies like gene and cell therapies, among others.

A leading driver of the global CDx market is the strong collaboration and partnership environment witnessed within pharma and diagnostic developers.Several mergers and acquisitions in recent years have been focused on expanding technical expertise in the precision diagnostics sector, next-generation sequencing (NGS) assays and liquid biopsy, all of them offering opportunities in the CDx development sector.

The U.S. has been on the forefront of this market with strong support from the FDA, which encourages the adoption of state-of-the-art diagnostic methods and has extended support for codevelopment of drugs with their CDx. Other countries, including some in Europe and several in the Asia-
Pacific region, are also updating or establishing their in vitro diagnostics (IVD) regulations to adopt CDx. The reimbursement situation has also seen a positive trend in this market, with many public systems providing coverage for CDx, including NGS multiplex assays.

However, certain challenges for this market remain.The lack of coordination and misaligned financial motivations for pharma and diagnostic developers have led to a slower-than-expected development in the CDx sector.

High costs of development, need for regulatory approvals and strong competition from the LDTs have been the major challenges.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on